Share Price and Basic Stock Data
Last Updated: October 30, 2025, 11:32 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Global Longlife Hospital and Research Ltd operates in the Hospitals & Medical Services industry, currently priced at ₹22.50 with a market capitalization of ₹23.6 Cr. The company has reported fluctuating sales figures, peaking at ₹19.94 Cr in September 2021, but declining significantly to ₹12.33 Cr by September 2023. The trailing twelve-month (TTM) sales for the year ending March 2025 stood at ₹0.31 Cr, indicating a concerning downward trend in revenue. The company’s expenses have also declined from ₹13.18 Cr in September 2021 to ₹9.62 Cr in September 2023, but this reduction has not kept pace with the decline in sales. The operating profit margin (OPM) showed a notable high of 33.90% in September 2021 but has since deteriorated, standing at 21.98% in September 2023. This volatility in revenue and profitability raises concerns regarding the company’s operational stability and market positioning.
Profitability and Efficiency Metrics
The profitability metrics of Global Longlife Hospital reflect significant fluctuations. The net profit peaked at ₹6.17 Cr in September 2021 but fell drastically to ₹1.03 Cr in September 2023, with a trailing twelve-month net profit of ₹0.20 Cr for March 2025. Earnings per share (EPS) also mirrored this trend, with a high of ₹8.81 in September 2021 and plummeting to ₹0.19 by March 2025. The company recorded a return on equity (ROE) of 17.7%, which is generally considered healthy, although the return on capital employed (ROCE) stood lower at 13.7%, indicating less efficiency in utilizing capital. The cash conversion cycle (CCC) has ballooned to 376.77 days by March 2025, suggesting significant inefficiencies in managing working capital. Such a prolonged CCC may hinder liquidity and operational efficiency, critical factors for sustaining profitability in the healthcare sector.
Balance Sheet Strength and Financial Ratios
Global Longlife Hospital’s balance sheet indicates a solid foundation with zero borrowings as of March 2025, reflecting prudent financial management. The company’s reserves have increased from ₹5.35 Cr in March 2019 to ₹16.29 Cr in March 2025, showcasing a strengthening asset base. The price-to-book value (P/BV) ratio stands at 0.74x, suggesting that the stock may be undervalued relative to its book value. However, the interest coverage ratio (ICR) of 3.10x remains indicative of adequate earnings to cover interest obligations, despite the absence of debt. The current ratio is exceptionally high at 405.69, signaling excellent short-term liquidity. However, the declining trend in total assets from ₹75.94 Cr in March 2023 to ₹26.85 Cr in March 2025 raises concerns about asset utilization and overall financial health, necessitating a closer examination of operational strategies.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Global Longlife Hospital reveals a stable promoter holding of 54.90% as of March 2025, which may instill confidence among investors regarding management stability. The public holding stands at 45.10%, with a total of 917 shareholders, indicating a relatively diversified ownership structure. However, the decline in the number of shareholders from 948 in September 2022 to 917 in March 2025 may reflect waning investor interest or confidence amid the company’s declining financial metrics. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) further underscores a lack of institutional backing, which is often a red flag for potential investors. This concentration of ownership and absence of institutional investment could impact share price volatility and market perception.
Outlook, Risks, and Final Insight
Looking ahead, Global Longlife Hospital faces several challenges and opportunities. The significant decline in revenue and profitability raises concerns about its operational viability. Key risks include an extended cash conversion cycle, declining sales, and potential liquidity issues, which could impede growth and investor confidence. Conversely, the zero-debt position and increasing reserves present a strong foundation for potential recovery. If the company can stabilize its operations and improve revenue generation, it may regain investor confidence and market share. Additionally, strategic partnerships or operational efficiencies could enhance profitability. However, without addressing the current inefficiencies and maintaining financial discipline, the company may struggle to navigate the competitive healthcare landscape effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Global Longlife Hospital and Research Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 45.7 Cr. | 136 | 195/135 | 6.14 | 115 | 2.57 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 24.9 Cr. | 23.7 | 37.6/0.00 | 25.5 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 12.6 Cr. | 12.2 | 23.4/12.0 | 140 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 125 Cr. | 66.8 | 98.7/51.4 | 27.2 | 16.1 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 22.3 Cr. | 4.13 | 7.73/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 28,929.00 Cr | 869.53 | 70.99 | 95.14 | 0.30% | 15.48% | 14.81% | 9.04 |
All Competitor Stocks of Global Longlife Hospital and Research Ltd
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 19.94 | 12.87 | 11.80 | 11.70 | 12.33 | 1.18 | 0.58 | 0.00 |
| Expenses | 13.18 | 11.61 | 10.03 | 9.44 | 9.62 | 4.20 | 4.39 | 0.35 |
| Operating Profit | 6.76 | 1.26 | 1.77 | 2.26 | 2.71 | -3.02 | -3.81 | -0.35 |
| OPM % | 33.90% | 9.79% | 15.00% | 19.32% | 21.98% | -255.93% | -656.90% | |
| Other Income | 0.07 | 0.16 | 0.07 | 0.17 | 0.02 | 0.04 | 5.69 | -0.67 |
| Interest | 0.09 | 1.31 | 0.20 | 0.20 | 0.41 | 0.36 | 0.28 | 0.00 |
| Depreciation | 0.58 | 0.57 | 0.58 | 0.59 | 0.61 | 0.64 | 0.48 | 0.00 |
| Profit before tax | 6.16 | -0.46 | 1.06 | 1.64 | 1.71 | -3.98 | 1.12 | -1.02 |
| Tax % | 0.00% | -78.26% | 29.25% | 35.37% | 39.77% | -19.10% | -11.61% | 2.94% |
| Net Profit | 6.17 | -0.10 | 0.76 | 1.07 | 1.03 | -3.22 | 1.24 | -1.04 |
| EPS in Rs | 8.81 | -0.14 | 0.72 | 1.02 | 0.98 | -3.07 | 1.18 | -0.99 |
Last Updated: May 31, 2025, 5:54 am
Below is a detailed analysis of the quarterly data for Global Longlife Hospital and Research Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.58 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 0.58 Cr..
- For Expenses, as of Mar 2025, the value is 0.35 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.39 Cr. (Sep 2024) to 0.35 Cr., marking a decrease of 4.04 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.35 Cr.. The value appears strong and on an upward trend. It has increased from -3.81 Cr. (Sep 2024) to -0.35 Cr., marking an increase of 3.46 Cr..
- For OPM %, as of Mar 2025, the value is 0.00%. The value appears strong and on an upward trend. It has increased from -656.90% (Sep 2024) to 0.00%, marking an increase of 656.90%.
- For Other Income, as of Mar 2025, the value is -0.67 Cr.. The value appears to be declining and may need further review. It has decreased from 5.69 Cr. (Sep 2024) to -0.67 Cr., marking a decrease of 6.36 Cr..
- For Interest, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.28 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 0.28 Cr..
- For Depreciation, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.48 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 0.48 Cr..
- For Profit before tax, as of Mar 2025, the value is -1.02 Cr.. The value appears to be declining and may need further review. It has decreased from 1.12 Cr. (Sep 2024) to -1.02 Cr., marking a decrease of 2.14 Cr..
- For Tax %, as of Mar 2025, the value is 2.94%. The value appears to be increasing, which may not be favorable. It has increased from -11.61% (Sep 2024) to 2.94%, marking an increase of 14.55%.
- For Net Profit, as of Mar 2025, the value is -1.04 Cr.. The value appears to be declining and may need further review. It has decreased from 1.24 Cr. (Sep 2024) to -1.04 Cr., marking a decrease of 2.28 Cr..
- For EPS in Rs, as of Mar 2025, the value is -0.99. The value appears to be declining and may need further review. It has decreased from 1.18 (Sep 2024) to -0.99, marking a decrease of 2.17.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 1:02 pm
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Sales | 33.44 | 33.32 | 32.70 | 32.44 | 23.38 | 13.46 | 0.31 |
| Expenses | 26.61 | 29.88 | 27.26 | 24.14 | 19.30 | 13.68 | 4.45 |
| Operating Profit | 6.83 | 3.44 | 5.44 | 8.30 | 4.08 | -0.22 | -4.14 |
| OPM % | 20.42% | 10.32% | 16.64% | 25.59% | 17.45% | -1.63% | -1,335.48% |
| Other Income | 0.08 | 0.03 | 0.06 | 0.17 | 0.24 | 0.00 | 5.02 |
| Interest | 2.07 | 2.41 | 2.44 | 1.62 | 0.45 | 0.80 | 0.30 |
| Depreciation | 2.15 | 2.13 | 1.31 | 1.14 | 1.17 | 1.25 | 0.48 |
| Profit before tax | 2.69 | -1.07 | 1.75 | 5.71 | 2.70 | -2.27 | 0.10 |
| Tax % | 49.07% | -18.69% | -16.57% | 37.30% | 32.59% | -3.52% | -100.00% |
| Net Profit | 1.36 | -0.86 | 2.05 | 3.57 | 1.83 | -2.19 | 0.20 |
| EPS in Rs | 1.94 | -1.23 | 2.93 | 5.10 | 1.74 | -2.09 | 0.19 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -163.24% | 338.37% | 74.15% | -48.74% | -219.67% | 109.13% |
| Change in YoY Net Profit Growth (%) | 0.00% | 501.61% | -264.23% | -122.89% | -170.93% | 328.80% |
Global Longlife Hospital and Research Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -61% |
| 3 Years: | -79% |
| TTM: | -98% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -119% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -33% |
| 1 Year: | -41% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | -4% |
| Last Year: | -18% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: August 11, 2025, 4:04 pm
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 7.00 | 7.00 | 7.00 | 7.00 | 10.50 | 10.50 | 10.50 |
| Reserves | 5.35 | 4.49 | 6.68 | 9.96 | 53.79 | 15.43 | 16.29 |
| Borrowings | 27.18 | 23.51 | 17.04 | 8.69 | 9.29 | 12.74 | 0.00 |
| Other Liabilities | 3.77 | 6.92 | 6.06 | 8.33 | 2.36 | 3.07 | 0.06 |
| Total Liabilities | 43.30 | 41.92 | 36.78 | 33.98 | 75.94 | 41.74 | 26.85 |
| Fixed Assets | 20.17 | 18.72 | 17.46 | 16.71 | 16.52 | 17.27 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 1.03 | 0.00 | 0.00 |
| Investments | 0.10 | 0.10 | 0.47 | 0.10 | 0.10 | 0.03 | 0.03 |
| Other Assets | 23.03 | 23.10 | 18.85 | 17.17 | 58.29 | 24.44 | 26.82 |
| Total Assets | 43.30 | 41.92 | 36.78 | 33.98 | 75.94 | 41.74 | 26.85 |
Below is a detailed analysis of the balance sheet data for Global Longlife Hospital and Research Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 10.50 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.50 Cr..
- For Reserves, as of Mar 2025, the value is 16.29 Cr.. The value appears strong and on an upward trend. It has increased from 15.43 Cr. (Mar 2024) to 16.29 Cr., marking an increase of 0.86 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 12.74 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 12.74 Cr..
- For Other Liabilities, as of Mar 2025, the value is 0.06 Cr.. The value appears to be improving (decreasing). It has decreased from 3.07 Cr. (Mar 2024) to 0.06 Cr., marking a decrease of 3.01 Cr..
- For Total Liabilities, as of Mar 2025, the value is 26.85 Cr.. The value appears to be improving (decreasing). It has decreased from 41.74 Cr. (Mar 2024) to 26.85 Cr., marking a decrease of 14.89 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 17.27 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 17.27 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.03 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.03 Cr..
- For Other Assets, as of Mar 2025, the value is 26.82 Cr.. The value appears strong and on an upward trend. It has increased from 24.44 Cr. (Mar 2024) to 26.82 Cr., marking an increase of 2.38 Cr..
- For Total Assets, as of Mar 2025, the value is 26.85 Cr.. The value appears to be declining and may need further review. It has decreased from 41.74 Cr. (Mar 2024) to 26.85 Cr., marking a decrease of 14.89 Cr..
Notably, the Reserves (16.29 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | -20.35 | -20.07 | -11.60 | -0.39 | -5.21 | -12.96 | -4.14 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 94.85 | 68.68 | 87.51 | 100.25 | 151.43 | 52.88 | 376.77 |
| Inventory Days | 169.49 | 157.97 | 34.46 | 88.98 | 69.12 | 131.64 | 0.00 |
| Days Payable | 229.91 | 391.69 | 138.68 | 432.74 | 110.43 | 765.90 | |
| Cash Conversion Cycle | 34.44 | -165.03 | -16.71 | -243.52 | 110.13 | -581.38 | 376.77 |
| Working Capital Days | 19.21 | 12.16 | 7.14 | -29.70 | 344.86 | -238.36 | 1,283.39 |
| ROCE % | 3.81% | 12.75% | 26.22% | 6.35% | -2.51% | -13.69% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.19 | -2.08 | 1.79 | 5.11 | 2.92 |
| Diluted EPS (Rs.) | 0.19 | -2.08 | 1.79 | 5.11 | 2.92 |
| Cash EPS (Rs.) | 0.64 | -0.89 | 2.85 | 6.74 | 5.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 25.51 | 24.70 | 61.23 | 24.23 | 19.54 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 25.51 | 24.70 | 61.23 | 24.23 | 19.54 |
| Revenue From Operations / Share (Rs.) | 0.54 | 12.87 | 22.38 | 46.88 | 46.72 |
| PBDIT / Share (Rs.) | 0.81 | -0.23 | 4.07 | 11.79 | 8.67 |
| PBIT / Share (Rs.) | 0.35 | -1.43 | 2.96 | 10.15 | 5.98 |
| PBT / Share (Rs.) | 0.09 | -2.16 | 2.58 | 8.16 | 2.51 |
| Net Profit / Share (Rs.) | 0.18 | -2.08 | 1.74 | 5.11 | 2.92 |
| PBDIT Margin (%) | 148.50 | -1.83 | 18.18 | 25.14 | 18.56 |
| PBIT Margin (%) | 65.02 | -11.08 | 13.22 | 21.66 | 12.81 |
| PBT Margin (%) | 17.18 | -16.76 | 11.52 | 17.40 | 5.37 |
| Net Profit Margin (%) | 34.41 | -16.19 | 7.77 | 10.89 | 6.25 |
| Return on Networth / Equity (%) | 0.74 | -8.43 | 2.84 | 21.06 | 14.96 |
| Return on Capital Employeed (%) | 1.40 | -5.09 | 4.56 | 35.19 | 15.94 |
| Return On Assets (%) | 0.74 | -5.24 | 2.40 | 10.51 | 5.56 |
| Long Term Debt / Equity (X) | 0.00 | 0.13 | 0.05 | 0.16 | 0.91 |
| Total Debt / Equity (X) | 0.00 | 0.49 | 0.14 | 0.51 | 0.91 |
| Asset Turnover Ratio (%) | 0.01 | 0.22 | 0.42 | 0.92 | 0.85 |
| Current Ratio (X) | 405.69 | 0.31 | 4.28 | 0.82 | 1.13 |
| Quick Ratio (X) | 405.69 | 0.28 | 4.17 | 0.75 | 1.06 |
| Inventory Turnover Ratio (X) | 2.64 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 3.10 | -0.32 | 10.67 | 5.90 | 2.50 |
| Interest Coverage Ratio (Post Tax) (X) | 1.72 | -1.85 | 5.56 | 3.55 | 1.84 |
| Enterprise Value (Cr.) | -1.58 | 53.35 | 52.71 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | -2.74 | 3.95 | 2.24 | 0.00 | 0.00 |
| EV / EBITDA (X) | -1.85 | -215.57 | 12.33 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 34.48 | 3.03 | 2.00 | 0.00 | 0.00 |
| Price / BV (X) | 0.74 | 1.58 | 0.73 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 34.54 | 3.03 | 2.00 | 0.00 | 0.00 |
| EarningsYield | 0.01 | -0.05 | 0.03 | 0.00 | 0.00 |
After reviewing the key financial ratios for Global Longlife Hospital and Research Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 5. It has increased from -2.08 (Mar 24) to 0.19, marking an increase of 2.27.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 5. It has increased from -2.08 (Mar 24) to 0.19, marking an increase of 2.27.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 3. It has increased from -0.89 (Mar 24) to 0.64, marking an increase of 1.53.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.51. It has increased from 24.70 (Mar 24) to 25.51, marking an increase of 0.81.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.51. It has increased from 24.70 (Mar 24) to 25.51, marking an increase of 0.81.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.54. It has decreased from 12.87 (Mar 24) to 0.54, marking a decrease of 12.33.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.81. This value is below the healthy minimum of 2. It has increased from -0.23 (Mar 24) to 0.81, marking an increase of 1.04.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.35. This value is within the healthy range. It has increased from -1.43 (Mar 24) to 0.35, marking an increase of 1.78.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from -2.16 (Mar 24) to 0.09, marking an increase of 2.25.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.18. This value is below the healthy minimum of 2. It has increased from -2.08 (Mar 24) to 0.18, marking an increase of 2.26.
- For PBDIT Margin (%), as of Mar 25, the value is 148.50. This value is within the healthy range. It has increased from -1.83 (Mar 24) to 148.50, marking an increase of 150.33.
- For PBIT Margin (%), as of Mar 25, the value is 65.02. This value exceeds the healthy maximum of 20. It has increased from -11.08 (Mar 24) to 65.02, marking an increase of 76.10.
- For PBT Margin (%), as of Mar 25, the value is 17.18. This value is within the healthy range. It has increased from -16.76 (Mar 24) to 17.18, marking an increase of 33.94.
- For Net Profit Margin (%), as of Mar 25, the value is 34.41. This value exceeds the healthy maximum of 10. It has increased from -16.19 (Mar 24) to 34.41, marking an increase of 50.60.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 15. It has increased from -8.43 (Mar 24) to 0.74, marking an increase of 9.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 10. It has increased from -5.09 (Mar 24) to 1.40, marking an increase of 6.49.
- For Return On Assets (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 5. It has increased from -5.24 (Mar 24) to 0.74, marking an increase of 5.98.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.13 (Mar 24) to 0.00, marking a decrease of 0.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.49 (Mar 24) to 0.00, marking a decrease of 0.49.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.01. It has decreased from 0.22 (Mar 24) to 0.01, marking a decrease of 0.21.
- For Current Ratio (X), as of Mar 25, the value is 405.69. This value exceeds the healthy maximum of 3. It has increased from 0.31 (Mar 24) to 405.69, marking an increase of 405.38.
- For Quick Ratio (X), as of Mar 25, the value is 405.69. This value exceeds the healthy maximum of 2. It has increased from 0.28 (Mar 24) to 405.69, marking an increase of 405.41.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.64. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 2.64, marking an increase of 2.64.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.10. This value is within the healthy range. It has increased from -0.32 (Mar 24) to 3.10, marking an increase of 3.42.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.72. This value is below the healthy minimum of 3. It has increased from -1.85 (Mar 24) to 1.72, marking an increase of 3.57.
- For Enterprise Value (Cr.), as of Mar 25, the value is -1.58. It has decreased from 53.35 (Mar 24) to -1.58, marking a decrease of 54.93.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is -2.74. This value is below the healthy minimum of 1. It has decreased from 3.95 (Mar 24) to -2.74, marking a decrease of 6.69.
- For EV / EBITDA (X), as of Mar 25, the value is -1.85. This value is below the healthy minimum of 5. It has increased from -215.57 (Mar 24) to -1.85, marking an increase of 213.72.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 34.48. This value exceeds the healthy maximum of 3. It has increased from 3.03 (Mar 24) to 34.48, marking an increase of 31.45.
- For Price / BV (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. It has decreased from 1.58 (Mar 24) to 0.74, marking a decrease of 0.84.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 34.54. This value exceeds the healthy maximum of 3. It has increased from 3.03 (Mar 24) to 34.54, marking an increase of 31.51.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.01, marking an increase of 0.06.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Global Longlife Hospital and Research Ltd:
- Net Profit Margin: 34.41%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.4% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.74% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 405.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 70.99)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 34.41%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | 703, Sankalp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road, Ahmedabad Gujarat 380059 | investor@globalhospital.co.in http://www.globalhospital.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dhruv Jani | Managing Director |
| Ms. Hetal Thakkar | Executive Director & CFO |
| Mrs. Sucheta Jani | Non Executive Director |
| Mr. Manasvi Thapar | Independent Director |
| Mr. Sandeep Shah | Independent Director |
FAQ
What is the intrinsic value of Global Longlife Hospital and Research Ltd?
Global Longlife Hospital and Research Ltd's intrinsic value (as of 03 November 2025) is 55.25 which is 133.12% higher the current market price of 23.70, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 24.9 Cr. market cap, FY2025-2026 high/low of 37.6/0.00, reserves of ₹16.29 Cr, and liabilities of 26.85 Cr.
What is the Market Cap of Global Longlife Hospital and Research Ltd?
The Market Cap of Global Longlife Hospital and Research Ltd is 24.9 Cr..
What is the current Stock Price of Global Longlife Hospital and Research Ltd as on 03 November 2025?
The current stock price of Global Longlife Hospital and Research Ltd as on 03 November 2025 is 23.7.
What is the High / Low of Global Longlife Hospital and Research Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Global Longlife Hospital and Research Ltd stocks is 37.6/0.00.
What is the Stock P/E of Global Longlife Hospital and Research Ltd?
The Stock P/E of Global Longlife Hospital and Research Ltd is .
What is the Book Value of Global Longlife Hospital and Research Ltd?
The Book Value of Global Longlife Hospital and Research Ltd is 25.5.
What is the Dividend Yield of Global Longlife Hospital and Research Ltd?
The Dividend Yield of Global Longlife Hospital and Research Ltd is 0.00 %.
What is the ROCE of Global Longlife Hospital and Research Ltd?
The ROCE of Global Longlife Hospital and Research Ltd is 13.7 %.
What is the ROE of Global Longlife Hospital and Research Ltd?
The ROE of Global Longlife Hospital and Research Ltd is 17.7 %.
What is the Face Value of Global Longlife Hospital and Research Ltd?
The Face Value of Global Longlife Hospital and Research Ltd is 10.0.